Patient-specific tumor neoantigen–HLA peptide complex (NeoAg-HLA complex)

Patient-specific tumor neoantigen–HLA peptide complexes are unique molecular assemblies formed when mutated proteins within a cancer cell are processed into short peptides and presented on the cell surface by Human Leukocyte Antigen (HLA) molecules (Source: NIH, 2023). These complexes are the primary signal for the adaptive immune system to distinguish malignant cells from healthy tissue, as the neoantigens are derived from somatic mutations that are absent in the patient's germline (Source: PubMed, 2022). Because they are exclusively expressed on tumor cells, these pHLA (peptide-HLA) complexes serve as ideal targets for precision immunotherapies, including personalized vaccines and T-cell receptor (TCR)-engineered T-cell therapies (Source: Nature, 2021). Therapeutic interventions such as mRNA-4157 and Autogene cevumeran are designed to prime the immune system to recognize these specific complexes, thereby inducing a potent and selective cytotoxic T-lymphocyte response (Source: Merck/Moderna, 2023; BioNTech, 2024). Additionally, advanced platforms like TCR-mimic antibodies and bispecific T-cell engagers are being developed to bypass the need for endogenous T-cell activation by directly binding the neoantigen-HLA complex (Source: NIH, 2024). Despite their high specificity, the clinical success of targeting these complexes depends on overcoming challenges such as tumor heterogeneity, HLA loss of heterozygosity, and the accurate computational prediction of immunogenic neoepitopes (Source: Frontiers in Immunology, 2023).

Other names

Tumor-specific antigen-MHC complexNeoepitope-HLA complexMutant peptide-MHC complexpHLA complexpMHC complexTSA-HLA complex

Recognition of the mutant peptide-HLA complex by endogenous or engineered T-cell receptors (TCRs) or TCR-mimic antibodies to trigger a targeted cytotoxic immune response against tumor cells (Source: NIH, 2023; Kactus Bio, 2023).